Belhaven Biopharma, founded with a mission to enhance patient access to lifesaving medications, focuses on the development and production of clinical trial materials. The company specializes in scaling up production for clinical trials, preparing and filing Investigational New Drug (IND) applications, and conducting pilot human clinical trials. Their flagship product, Nasdepi®, is a dry powder intranasal epinephrine designed for the treatment of anaphylaxis, aiming to provide a quick, effective, and painless solution.

Notable figures associated with Belhaven Biopharma include experts in drug development and formulation who have contributed to the company's patented technology. The company has achieved significant milestones in advancing its intranasal drug delivery system, positioning itself as a leader in this niche market. The impact of Belhaven Biopharma is evident in its innovative approach to drug administration, potentially transforming emergency treatment for anaphylaxis and improving patient outcomes.